DelveInsight’s ‘Peripheral Arterial Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and Peripheral Arterial Disease pipeline therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Peripheral Arterial Disease pipeline domain.
For further information on the Peripheral Arterial Disease Pipeline report offerings, download free sample @ Peripheral Arterial Disease Pipeline Insight
Key takeaways from the Peripheral Arterial Disease Pipeline Report
Request a sample and discover the recent breakthroughs happening in Peripheral Arterial Disease pipeline landscape @ Peripheral Arterial Disease Pipeline Outlook Report
Peripheral Arterial Disease Overview
Peripheral artery disease (PAD) refers to diseases of the blood vessels located outside the heart and brain. PAD is a chronic disease in which plaque builds up in the arteries of the legs. It is more common in people who are 65 or older, but can occur at nearly any age. Smoking; high blood pressure; high cholesterol or triglycerides; diabetes; kidney failure; and obesity increase risk for PAD. While many people with peripheral artery disease have mild or no symptoms, some people have leg pain when walking.
Emerging Peripheral Arterial Disease Drugs
Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently in Phase III stage of development for the treatment of patients with Type 2Diabetes Mellitus, and Peripheral Arterial Disease.
Engensis (VM202) is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed. Helixmith’s non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. Engensis (VM202) has the potential to promote blood vessel formation in the ischemic area by HGF-based angiogenesis. In addition, the HGF-based angiogenesis may also contribute to cardiac muscle function improvement through the suppression of apoptosis and cardiac fibrosis.
Find out more about the diagnosis and treatment of patients with Peripheral Arterial Disease @ Peripheral Arterial Disease Ongoing Clinical Trials Analysis
Peripheral Arterial Disease Key Companies and Pipeline Therapies
Peripheral Arterial Disease Pipeline Therapeutics Assessment
Phases
Route of Administration
Molecule Type
Scope of the Peripheral Arterial Disease Pipeline Report
Dive deep into rich insights for Peripheral Arterial Disease Emerging Therapies and assessment; visit @ Peripheral Arterial Disease Treatment Landscape
Table of Content
For further information on the Peripheral Arterial Disease Pipeline therapeutics, reach out @ Peripheral Arterial Disease Companies & Therapies
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting/conference-coverage-services